Carfilzomib for Injection 30mg
CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.
Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.
CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.
This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.
Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.
Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.
View Details
Enzalutamide Tablets 160mg
ENZALIEVA Enzalutamide Tablets 160mg is an advanced anticancer medicine used for the treatment of prostate cancer in adult patients. It contains Enzalutamide, a powerful androgen receptor inhibitor that helps slow down the growth and spread of prostate cancer cells. This medicine is commonly prescribed by oncologists as part of hormone therapy for patients suffering from advanced or metastatic prostate cancer.
Prostate cancer is one of the most common cancers affecting men worldwide. Cancer cells in the prostate often depend on male hormones called androgens, especially testosterone, for growth and survival. Enzalutamide works by blocking the action of these hormones, helping reduce the ability of cancer cells to grow and multiply. Due to its targeted mechanism of action, ENZALIEVA is widely used in modern oncology treatment protocols for prostate cancer management.
ENZALIEVA Enzalutamide Tablets 160mg is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine is commonly recommended in patients with:
Metastatic castration-resistant prostate cancer (mCRPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC)
This anticancer medicine is usually prescribed when prostate cancer continues to progress despite reduced testosterone levels or hormonal treatment. Doctors may use ENZALIEVA alone or in combination with other therapies depending on the patient’s condition, cancer stage, and overall treatment plan.
Enzalutamide Tablets are known for helping improve disease management by delaying cancer progression and supporting overall treatment outcomes. The medicine has become an important part of prostate cancer therapy due to its effectiveness in controlling androgen receptor activity, which plays a major role in prostate cancer growth.
Patients should use this medicine strictly under the supervision of qualified healthcare professionals. Proper medical monitoring and regular health checkups are important during treatment to ensure better response and patient safety.
View Details
Etoposide Injection IP 100 MG
VEPELIEVA Etoposide Injection IP 100MG is a widely used anticancer chemotherapy medicine formulated for the treatment of different types of cancers. It contains Etoposide, an effective oncology medicine that helps slow down or stop the growth of cancer cells in the body. This injection is commonly used in hospitals, cancer treatment centers, and oncology clinics under the supervision of experienced healthcare professionals.
Etoposide belongs to a class of medicines known as topoisomerase inhibitors. It works by interfering with the DNA replication process of rapidly growing cancer cells. By damaging the DNA of these abnormal cells, the medicine helps prevent their growth and spread. Due to its effectiveness in chemotherapy treatment protocols, Etoposide Injection IP 100MG is commonly prescribed in combination with other anticancer medicines for better treatment outcomes.
VEPELIEVA is manufactured under high pharmaceutical quality standards to ensure safety, purity, and effectiveness. The medicine is designed to meet the requirements of modern oncology treatment and is trusted by healthcare professionals for use in multiple cancer therapies.
This oncology injection is mainly recommended for patients diagnosed with cancers such as small cell lung cancer, testicular cancer, leukemia, lymphoma, and other severe malignant conditions. Doctors may prescribe this medicine alone or as part of combination chemotherapy depending on the patient’s medical condition, stage of cancer, and overall treatment plan.
Chemotherapy medicines like VEPELIEVA are an important part of cancer management because they help reduce the spread of cancer cells and improve the effectiveness of treatment protocols. Since cancer cells multiply rapidly, medicines like Etoposide are specially designed to target these abnormal cells and reduce their growth inside the body.
VEPELIEVA Etoposide Injection IP 100MG is intended strictly for medical use and should only be administered by trained healthcare professionals in clinical settings. Patients are advised not to self-administer this injection. Proper medical monitoring, laboratory testing, and regular health assessments are usually recommended during chemotherapy treatment to ensure patient safety and better treatment response.
This anticancer injection is known for its role in advanced oncology treatment plans and is considered an important chemotherapy medicine in cancer care. With proper medical supervision and supportive care, Etoposide Injection can help improve treatment management in cancer patients.
View Details
Ribavirin 200mg
Ribavirin 200 mg is a broad-spectrum antiviral medication used in combination with other antiviral agents for the treatment of chronic viral infections, primarily Hepatitis C and certain viral respiratory infections.
RIBALIEVA 200 MG works by inhibiting viral replication, helping to reduce viral load and improve treatment outcomes when used as part of combination therapy.
View Details
Entecavir 0.5mg
Entecavir 0.5 mg is an antiviral medication used in the treatment of chronic Hepatitis B virus (HBV) infection. It belongs to the class of medicines known as nucleoside analog reverse transcriptase inhibitors (NRTIs).
ENTELIEVA 0.5 MG works by inhibiting the replication of Hepatitis B virus, thereby reducing viral load, improving liver function, and preventing further liver damage such as cirrhosis or liver cancer.
View Details
Menotropin Injection 150IU
Menotropin Injection 150 IU is a hormonal preparation containing Human Menopausal Gonadotropin (HMG), which provides a balanced combination of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH).
ALLIE-HMG 150 IU is used in the treatment of infertility in both women and men. It works by stimulating ovarian follicle development in women and enhancing sperm production in men with hormone deficiencies.
View Details
Menotropin Injection 75IU
Menotropin Injection 75 IU is a gonadotropin hormone preparation containing Human Menopausal Gonadotropin (HMG), which is a combination of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH).
It is used to treat infertility in both women and men by stimulating the development of reproductive cells.
ALLIE-HMG 75 IU helps in ovarian follicle development in women and sperm production in men when natural hormone levels are insufficient.
View Details
Ibrutinib Capsules 140mg
IBRULIEVA contains Ibrutinib, a first-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It blocks BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
View Details
Melphalan Tablet IP 2mg
MELIEVA contains Melphalan, an alkylating anticancer agent. It works by cross-linking DNA strands, thereby inhibiting DNA and RNA synthesis and leading to the death of rapidly dividing cancer cells.
View Details
Aprepitant Capsules IP 125mg
APRELIEVA contains Aprepitant, an antiemetic drug belonging to the Neurokinin-1 (NK1) receptor antagonist class. It works by blocking substance P in the brain, thereby preventing chemotherapy-induced nausea and vomiting (CINV).
View Details
Acalabrutinib Capsules 100mg
ACALIEVA contains Acalabrutinib, a second-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It works by blocking BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
View Details
Erlotinib Tablets IP 150mg
ERLOLIEVA contains Erlotinib, an oral targeted anticancer medicine. It is a tyrosine kinase inhibitor (TKI) that selectively blocks the epidermal growth factor receptor (EGFR), thereby inhibiting tumor cell proliferation and survival—especially in EGFR-mutated cancers.
View Details
